Despite advances in pharmacotherapy, intervention devices and techniques, residual
cardiovascular risks still cause a large burden on public health. Whilst most guidelines …

With cardiovascular disease being the leading cause of morbidity and mortality worldwide,
effective and cost-efficient therapies to reduce cardiovascular risk are highly needed. Lipids …

Low-density lipoproteins (LDL) play a causal role in the development of atherosclerosis, and
reduction of LDL cholesterol with a statin is a cornerstone in prevention of cardiovascular …

Recent years have brought a significant amount of new results in the field of atherosclerosis.
A better understanding of the role of different lipoprotein particles in the formation of …

The past year was an exciting time for clinical lipidology when we learnt more about existing
therapies as well as therapies targeting novel pathways discovered through genetic studies …

Dyslipidaemias play a key role in determining cardiovascular risk; the discovery of statins
has contributed a very effective approach. However, many patients do not achieve, at the …

Dyslipidemia, characterized by a high level of lipids (cholesterol, triglycerides, or both), can
increase the risk of developing and progressing atherosclerosis. As atherosclerosis …

Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease (ASCVD).
There are abundant and unequivocal data to indicate that low-density lipoproteins (LDL) are …

Lp (a) remains the last major lipoprotein disorder without any specific therapy. With the
strong and accumulating data on its role as a causal risk factor for CVD, a rationale exists to …

The pathogenesis and progression of atherosclerosis are integrally connected to the
concentration and function of lipoproteins in various classes. This review examines existing …